What Mologic does

Mologic is a UK-based developer of point-of-care diagnostic devices founded in 2003 and headquartered in Thurleigh. The company operates in the paper diagnostics market, building rapid lateral-flow and related assay technologies designed for use outside traditional laboratory settings, with applications spanning infectious disease and global health. Its capital base is anchored by philanthropic and government institutions — including the Bill & Melinda Gates Foundation, the Wellcome Trust, the UK Department for International Development, and SBRI Healthcare — alongside UK growth-equity investors such as Calculus Capital and Foresight Group, suggesting a mission-driven orientation toward affordable, accessible diagnostics in low- and middle-income markets.

The company is led by co-founder and CSO Paul Davis, founder and CEO Mark Davis, executive chairman Chris Jones, CTO Tim Dwyer, and finance director Daniel Janes, providing both scientific and operational continuity. A related entity, Global Access Diagnostics (GADx), is referenced as a contract research organisation with its own web presence, indicating that Mologic may have incubated or spun out a commercial arm to extend manufacturing and distribution reach. Total disclosed funding is approximately $10.8 million across six rounds between 2015 and 2020, and the company is privately held with 11-50 employees. No detailed product catalogue, pricing model, customer roster, or revenue figures are disclosed in the available data, which limits visibility into commercial traction and unit economics.

Name

Mologic

Website

https://mologic.co.uk

Company type

Private

Founded year

2003

Headcount range

11–50 employees

Short description

Mologic is a UK-based, privately held developer of point-of-care paper diagnostic devices founded in 2003, serving global health and infectious disease applications with backing from philanthropic and government institutional funders.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841), Services-Testing Laboratories (8734)

akta.pro primary industry

Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow) (HLAAALAG)

akta.pro secondary industries

Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)

Keywords

• Point-of-care diagnostics
• Rapid diagnostic tests
• Lateral flow assays
• Diagnostic device development
• Contract research diagnostics

Headquarters

HQ city

Thurleigh

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Core offering

Mologic develops point-of-care diagnostic devices using lateral flow assay technology for the rapid detection of infectious diseases and other conditions without requiring laboratory infrastructure. The company focuses on low-resource and global health applications, delivering tests suitable for use in the field by healthcare workers and humanitarian responders.

Differentiator

Problem solved

Functional benefit

Products and services

• Point-of-Care Diagnostic Devices
• Contract Research and Development Services

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered minor and core.

• Mylab Discovery SolutionsminorOthers · 1 August 2023In August 2023, India-based Mylab Discovery Solutions launched two rapid dengue detection tests providing results in 15-20 minutes without laboratory requirements. Mentioned in context of paper diagnostics market growth alongside Mologic. Note: Mylab is referenced as a market competitor/peer, not as a direct partner.
• QIAGENcoreStrategic or Co-development Partner · 1 March 2023In March 2023, French pharmaceutical group Servier partnered with Germany's QIAGEN to co-develop a companion diagnostic test for IDH1 mutations in acute myeloid leukemia patients, based on positive Phase 3 AGILE study results. This partnership focuses on companion diagnostics development in the paper diagnostics/molecular diagnostics space.

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Direct peers

• Mylab Discovery Solutions: India-based developer of rapid point-of-care diagnostic tests including dengue, infectious disease and other lateral flow assays. Explicitly referenced as a market peer/competitor in the Mologic source data and operates in the same paper diagnostics / lateral flow category.
• QuidelOrtho: US-headquartered diagnostics company focused on rapid point-of-care immunoassays and lateral flow tests across infectious disease, reproductive health, and specialty diagnostics. Closely comparable to Mologic in POC rapid diagnostics format and menu.
• Access Bio: US/Korea-based manufacturer of rapid diagnostic tests, including lateral flow assays for infectious disease, with strong presence in global health and low-resource settings — directly overlapping Mologic's POC and global health focus.
• OraSure Technologies: US-based developer of rapid oral fluid and lateral flow diagnostic tests, including infectious disease and substance abuse applications. Comparable POC/rapid diagnostics business with a similar global health angle.
• Meridian Bioscience: US-based diagnostics company supplying lateral flow tests, EIA kits, and molecular diagnostic reagents for infectious disease. Overlaps directly with Mologic's lateral flow and IVD reagent focus.

Broad incumbents

• Abbott (Diagnostics): Global diagnostics leader with a large rapid diagnostics / POC portfolio (including the legacy Alere Binax lateral flow tests) across infectious disease, cardiometabolic, and consumer health. Operates in the same POC category as Mologic but at vastly greater scale.
• Becton Dickinson (BD): Global medical technology company with a substantial diagnostic systems business, including the BD Veritor lateral flow platform for POC infectious disease testing. Overlaps with Mologic's POC rapid test category.
• QIAGEN: Germany-based molecular diagnostics and sample technologies company active in companion diagnostics and IVD reagent manufacturing, including POC-adjacent formats. Referenced alongside Mologic in the broader diagnostics market context.
• bioMérieux: France-based in vitro diagnostics company with a portfolio spanning microbiology, immunoassays, and molecular diagnostics, including POC and rapid test offerings. Comparable in IVD / POC category at larger scale.

Emerging players

• Chembio Diagnostics: US-based small-cap diagnostics company developing POC rapid tests, with focus on infectious disease and global health markets. Closely comparable to Mologic in scale, format (lateral flow) and global health orientation.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/mologic
• LinkedInlinkedin.com/company/mologic

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mologic